The objective is to improve current diagnostics and to enable prevention-based approaches and to segregate patient populations (sub-typing) addressing the current responder/non-responder issues in Western medicine. The main objective is to discover novel biomarkers for two important chronic disease areas: type 2 diabetes and arthritis (osteoarthritis and rheumatoid arthritis).
Diagnostic discovery strategies will be based on “Disease phenotyping using metabolomics-based Systems Biology” and “ultra-weak photon emission”.
The production of biological light (ultra-weak photon emission or biophotons) within many types of cells and tissues is characteristic of a living organism. You will begin a journey of discovery about biophotons in relationshipto biological matter and about how such biophotons can be detected utilizing specialized very photon-sensitivetechnologies.
“A single pill to cure every rheumatoid arthritis patient is a dated idea,” explains Herman van Wietmarschen. “People react differently to drugs because their genetic make-up and their life habits aren’t the same. It’s time to figure out to which subgroup patients belong, to get every patient the best drug as soon as possible.”
Koko Wei is validating Traditional Chinese medicine diagnoses with metabolomics analyses. “There may be value in the combination of both paths.” She has recently finished her PhD research at the Sino-Dutch Centre for Preventive and Personalized Medicine.